DXC006

DRUG2 trials

Sponsors

Hangzhou DAC Biotechnology Co., Ltd.

Conditions

Advanced Solid TumorsHematological MalignanciesSmall Cell Lung Cancer

Phase 1

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

RecruitingNCT06224855

Hangzhou DAC Biotechnology Co., Ltd.Advanced Solid Tumors, Hematological Malignancies

Start: 2024-01-24End: 2027-12-31Target: 280Updated: 2026-06-22

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.

Not yet recruitingNCT07559929

Hangzhou DAC Biotechnology Co., Ltd.Small Cell Lung Cancer

Start: 2026-06-01End: 2030-12-30Target: 200Updated: 2026-05-29

Related Papers

DXC006, a first-in-class CD56-targeting antibody-drug conjugate, in advanced solid tumors: A first-in-human, phase I dose escalation clinical trial.

Journal of Clinical Oncology2026-05-27